RxDoctor Payments Data

Clara Kennedy, PA

Medical · Brookings, SDNPI 1437339496

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $282 of the $381 with a category attached, or 74.0%. 9 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 36.6% of the total.

$381in general payments, 2019–2025

Across 10 payments — averaging $38.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$140
  • Exelixis Inc.$99
  • Karyopharm Therapeutics Inc.$39
  • Accord Healthcare, Inc.$24
  • Sanofi$20
  • Genmab U.S., Inc.$17
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$28274%
  • Education$9926%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$381 in reported general payments places this provider in the 60th percentile of 43 medical providers in South Dakota.

See all medical providers in South Dakota

Medicare billing

Part B allowed, 2024
$61,551
Medicare patients
184
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$8,931
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$566
Tramadol Hcl24$400
Duloxetine Hcl14$400
Potassium Chloride20$385
Atorvastatin Calcium16$226
Pantoprazole Sodium21$216
Gabapentin17$195
Metoprolol Succinate13$155
Alprazolam17$135
Trazodone Hcl11$131
Quetiapine Fumarate13$112
Lisinopril12$106
Furosemide11$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$8,93118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 43 medical providers in South Dakota.

Other medical in Brookings

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →